Literature DB >> 11304875

Leiomyosarcoma after uterine artery embolization. A case report.

A Joyce1, S Hessami, D Heller.   

Abstract

BACKGROUND: Hysterectomy is the most common treatment for relieving symptoms attributable to uterine leiomyomas; however, alternatives to hysterectomy are becoming increasingly available. Uterine artery embolization is being used more frequently in this clinical setting. CASE: A leiomyosarcoma was diagnosed incidentally in a 51-year-old, nulliparous woman who underwent uterine artery embolization for symptomatic leiomyomata and subsequent total abdominal hysterectomy/bilateral salpingo-oophorectomy due to unsatisfactory results of the embolization procedure.
CONCLUSION: While the occurrence of preoperatively undiagnosed uterine leiomyosarcomas among patients undergoing hysterectomies has been reported, there are no reports of unsuspected leiomyosarcomas after uterine artery embolization. Criteria for selection of patients for the procedure should consider the possibility of leiomyosarcoma. With the increasing popularity of uterine artery embolization, cases like this are likely to be encountered in the future.

Entities:  

Mesh:

Year:  2001        PMID: 11304875

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  3 in total

Review 1.  [Long-term results after fibroid embolization].

Authors:  S Müller-Hülsbeck
Journal:  Radiologe       Date:  2008-07       Impact factor: 0.635

Review 2.  Clinical and periprocedural pain management for uterine artery embolization.

Authors:  Elizabeth Brooke Spencer; Peter Stratil; Heidi Mizones
Journal:  Semin Intervent Radiol       Date:  2013-12       Impact factor: 1.513

3.  Extravascular Dispersion of Polyvinyl Alcohol Microsphere Particles in Uterine Artery Embolization.

Authors:  L A Torres-de la Roche; C Cezar; S Hanif; R Devassy; H Krentel; J Hennefründ; R L De Wilde
Journal:  Biomed Res Int       Date:  2022-02-15       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.